Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 974-983

  Soutar, Marc P M ^a   Kim, Woo Yang ^b   Williamson, Ritchie ^a   Peggie, Mark ^a   Hastie, Charles James ^a   McLauchlan, Hilary ^a   Snider, William D ^b   Gordon Weeks, Phillip R ^c   Sutherland, Calum ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CRMP; GSK3; Knockout; Neuron; Splice variant; Tau

Indexed keywords

BETA CATENIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PROTEIN C JUN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA SPLICING;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMALS; BRAIN; CELL LINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; ISOENZYMES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; SUBSTRATE SPECIFICITY;

MAMMALIA;

EID: 77958597709     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06988.x     Document Type: Article

References (34)

1. Bain J., Plater L., Elliott M. et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315.
2. Beaulieu J. M., Zhang X., Rodriguiz R. M., Sotnikova T. D., Cools M. J., Wetsel W. C., Gainetdinov R. R. and Caron M. G. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc. Natl Acad. Sci. USA 105, 1333-1338.
3. Bhat R. V., Budd Haeberlein S. L. and Avila J. (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 1313-1317.
4. Boyle W. J., Smeal T., Defize L. H., Angel P., Woodgett J. R., Karin M. and Hunter T. (1991) Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64, 573-584.
5. Cadigan K. M. and Liu Y. I. (2006) Wnt signalling: complexity at the surface. J. Cell Sci. 118, 395-402.
6. Castano Z., Gordon-Weeks P. R. and Kypta R. M. (2010) The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth. J. Neurochem. 113, 117-130.
7. Cole A., Frame S. and Cohen P. (2004a) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 377, 249-255.
8. Cole A., Knebel A., Morrice N. A., Robertson L. S., Irving A. J., Connolly C. N. and Sutherland C. (2004b) GSK-3 phosphorylation of the Alzheimers epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J. Biol. Chem. 279, 50176-50180.
9. Cole A., Noble W. and Van Aalten L. et al. (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J. Neurochem. 103, 1132-1144.
10. Eom T. Y. and Jope R. S. (2009) Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol. Psychiatry 66, 494-502.
11. Frame S. and Cohen P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.
12. Goold R. G. and Gordon-Weeks P. R. (2001) Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. J. Cell Sci. 114, 4273-4284.
13. Gregory M. A., Qi Y. and Hann S. R. (2003) Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278, 51606-51612.
14. Hanger D. P., Seereeram A. and Noble W. (2009) Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Rev. Neurother. 9, 1647-1666.
15. Hoeflich K. P., Luo J., Rubie E. A., Tsao M.-S., Jin O. and Woodgett J. R. (2000) Requirement for GSK3beta in cell surival and NFkB activation. Nature 406, 86-90.
16. Holmes C. F., Kuret J., Chisholm A. A. and Cohen P. (1986) Identification of the sites on rabbit skeletal muscle protein phosphatase inhibitor-2 phosphorylated by casein kinase-II. Biochim. Biophys. Acta 870, 408-416.
17. Kaidanovich-Beilin O., Lipina T. V. and Takao K. et al. (2009) Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol. Brain 2, 35.
18. Kim W. Y., Wang X., Wu Y., Doble B. W., Patel S., Woodgett J. R. and Snider W. D. (2009) GSK-3 is a master regulator of neural progenitor homeostasis. Nat. Neurosci. 12, 1390-1397.
19. Kimura T., Yamashita S., Nakao S., Park J. M., Murayama M., Mizoroki T., Yoshiike Y., Sahara N. and Takashima A. (2008) GSK-3beta is required for memory reconsolidation in adult brain. PLoS ONE 3, e3540.
20. Liu C., Li Y., Semenov M., Han C., Baeg G.-H., Tan Y., Zhang Z., Lin X. and He X. (2002) Control of b-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847.
21. Liu K. J., Arron J. R., Stankunas K., Crabtree G. R. and Longaker M. T. (2007) Chemical rescue of cleft palate and midline defects in conditional GSK3b mice. Nature 446, 79-82.
22. Lochhead P. A., Kinstrie R., Sibbet G., Rawjee T., Morrice N. and Cleghon V. (2006) A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol. Cell 24, 627-633.
23. MacAulay K., Doble B. W., Patel S., Hansotia T., Sinclair E. M., Drucker D. J., Nagy A. and Woodgett J. R. (2007) Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab. 6, 329-337.
24. Morton S., Davis R. J., McLaren A. and Cohen P. (2003) A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J. 22, 3876-3886.
25. Mukai F., Ishiguro K., Sano Y. and Fujita S. C. (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 81, 1073-1083.
26. O'Brien W. T., Harper A. D., Jove F., Woodgett J. R., Maretto S., Piccolo S. and Klein P. S. (2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24, 6791-6798.
27. Park I. K., Roach P., Bondor J., Fox S. P. and DePaoli-Roach A. A. (1994) Molecular mechanism of the synergistic phosphorylation of phosphatase inhibitor-2. Cloning, expression, and site-directed mutagenesis of inhibitor-2. J. Biol. Chem. 269, 944-954.
28. Picking W. D., Kudlicki W., Kramer G., Hardesty B., Vandenheede J. R., Merlevede W., Park I. K. and DePaoli-Roach A. (1991) Fluorescence studies on the interaction of inhibitor 2 and okadaic acid with the catalytic subunit of type 1 phosphoprotein phosphatases. Biochemistry 30, 10280-10287.
29. Prickaerts J., Moechars D., Cryns K., Lenaerts I., Van Craenendonck H., Goris I., Daneels G., Bouwknecht J. A. and Steckler T. (2006) Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci. 26, 9022-9029.
30. mo-2. Eur. J. Biochem. 212, 581-588.
31. Sutherland C., Leighton I. A. and Cohen P. (1993b) Inactivation of glycogen synthase kinase-3β by phosphorylation; new kinase connections in insulin and growth factor signalling. Biochem. J. 296, 15-19.
32. Thornton T. M., Pedraza-Alva G. and Deng B. et al. (2008) Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320, 667-670.
33. Wagman A. S., Johnson K. W. and Bussiere D. E. (2004) Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 10, 1105-1137.
34. Wood-Kaczmar A., Kraus M., Ishiguro K., Philpott K. L. and Gordon-Weeks P. R. (2009) An alternatively spliced form of glycogen synthase kinase-3beta is targeted to growing neurites and growth cones. Mol. Cell. Neurosci. 42, 184-194.